| Q37352516 | A new approach to menopausal therapy: the tissue selective estrogen complex |
| Q37615069 | Abnormal bleeding during menopause hormone therapy: insights for clinical management |
| Q38161857 | Advances in menopausal therapy: the tissue-selective estrogen complex |
| Q38149162 | Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause |
| Q45227228 | Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women |
| Q36892860 | Care of the menopausal patient: a nurse practitioner's view |
| Q43267040 | Current state of hormone replacement therapy: the case for using trimegestone |
| Q39401965 | Dose-response analysis of effects of tibolone on climacteric symptoms |
| Q43662494 | Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism |
| Q43662497 | Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate |
| Q44648884 | Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results |
| Q50967090 | Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. |
| Q24658109 | Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society |
| Q52665446 | Estrogen therapy for osteoporosis in the modern era. |
| Q43801855 | Estrogens and women's health: a scary or a fairy tale? |
| Q36843105 | Health related quality of life after combined hormone replacement therapy: randomised controlled trial |
| Q56594031 | Hormone Therapy (I): Estrogens, Progestogens, and Androgens |
| Q34995241 | Hormone replacement therapy: optimising the dose and route of administration |
| Q34455239 | Hormone replacement therapy: the benefits in tailoring the regimen and dose |
| Q24201543 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q24241713 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q24246573 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q36970351 | Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. |
| Q35948695 | Neoplasia of the female reproductive tract: effects of hormone therapy |
| Q35948672 | New HRT options for the treatment of menopausal symptoms and the maintenance of quality of life in postmenopausal women |
| Q43225739 | Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results |
| Q44485605 | Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. |
| Q37808639 | Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE) |
| Q33949094 | Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate |
| Q39337263 | Should symptomatic menopausal women be offered hormone therapy? |
| Q45205625 | The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women |
| Q85013828 | The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis |
| Q35134590 | The menopausal transition: characteristics and management |
| Q50998685 | The osteoporosis dilemma. |
| Q35948662 | The rationale for low-dose hormonal therapy |
| Q37277298 | The tissue selective estrogen complex: a promising new menopausal therapy |
| Q37801227 | Tissue-Selective Agents: Selective Estrogen Receptor Modulators and the Tissue-Selective Estrogen Complex |
| Q37768158 | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms |
| Q46802787 | Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women |
| Q38429496 | Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy |